Oragenics, Inc. (ORAGENICS INC) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oragenics, Inc. on November 20, 2013. The report addresses an "Other Event" (Item 8.01) regarding the completion of a previously announced underwritten public offering of common stock.
Key Financial Metrics
The filing details a capital raise event rather than operational financial results. Key figures include:
- Shares Issued: 4,400,000 shares of common stock.
- Offering Price: $2.50 per share.
- Total Gross Proceeds: $11,000,000 (calculated as 4,400,000 shares x $2.50).
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions as of this date.
Material Changes
The primary material change is the increase in the company's outstanding share count and equity capital resulting from the completion of the public offering on November 20, 2013.
Guidance, Outlook, and Risks
This filing does not contain management guidance, future outlook, risk factors, or contingencies. It serves solely to disclose the completion of the equity offering. A press release dated November 20, 2013, is attached as Exhibit 99.1 and incorporated by reference.
Investor Verification Checklist
- Verify the net proceeds received after deducting underwriting discounts and commissions, as only the gross offering price is stated here.
- Review the attached Exhibit 99.1 (Press Release) for details on the use of proceeds.
- Confirm the updated total number of outstanding shares post-offering.
- Check subsequent filings for the impact of this capital raise on the company's cash position and operational runway.